Mylan's Lantus Rival Faces Fresh Attack
Sanofi Tries To Stop Biosimilar Via Supreme Court PTAB Review
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
